-
Another medicine for children may be on the market soon!
Time of Update: 2022-01-03
The industry believes that if the medicinal charcoal suspension particles declared this time are successfully approved, it will bring new treatment options to more children .
-
9 drugs facing 4.1 patent challenges under China's drug patent linkage system
Time of Update: 2022-01-03
If the patentee or interested parties have objections to the four types of patent declarations, they may, within 45 days from the date of publication of the drug marketing authorization application by the National Drug Evaluation Agency, determine whether the relevant technical solutions for the listed drugs fall within the protection scope of the relevant patent rights File a lawsuit with the people's court or request an administrative ruling from the patent administration department of the State Council .
-
With the continuous expansion of the API market, the pharmaceutical equipment industry will continue to benefit
Time of Update: 2022-01-03
With the advancement of centralized procurement policies, consistency evaluation, and drug-related approvals, as well as benefiting from the transfer of global orders, the scale of China's API industry has continued to expand in recent years .
-
DPP1 inhibitor ill-fated, AstraZeneca brensocatib changes hands and takes a turn for the better
Time of Update: 2022-01-03
In September 2020, Insmed announced that the Phase 2 clinical study WILLOW of brensocatib in the treatment of non-cystic fibrosis bronchiectasis (NCFBE) reached the primary endpoint .
-
The quantity of Chinese medicinal materials is small and the price is high. What impact will it have on Chinese medicine companies?
Time of Update: 2022-01-03
In fact, compared with pharmaceutical companies, the industry believes that the increase in the price of Chinese medicinal materials will have a greater impact on planting companies .
-
Enhertu secretly practiced side martial arts?
Time of Update: 2022-01-03
Drug source analysisDrug source analysisAt the SABCS annual meeting two years ago, Enhertu had a blockbuster at the beginning with the Phase II clinical results of Destiny-Breast01.
Enhertu uses severable linkers, so active substances can be released after entering tumor cells .
-
The third series of pharmaceutical excipients-functional indicators of pharmaceutical excipients (FRCs)
Time of Update: 2022-01-03
(1) Critical micelle concentration (CMC)It is an important indicator for surfactants to perform their functions.
-
2 billion large varieties!
Time of Update: 2022-01-03
On November 29, Buchang Pharmaceuticals announced that its wholly-owned subsidiary Shandong Danhong's parecoxib sodium for injection was approved for listing .
Parecoxib sodium for injection is a selective COX-2 inhibitor, and its terminal sales in China's public medical institutions will exceed 2 billion yuan in 2020 .
-
Pharmaceutical companies such as Xianju Pharmaceutical and Minova accept surveys from more than 10 institutions
Time of Update: 2022-01-03
In addition, in answering the company’s mid- and long-term strategic positioning and future development layout, Xianju Pharmaceutical said that the company has an integrated industrial chain of APIs and preparations, a complete manufacturing system (Chinese factories and Italian factories), and sales both domestic and foreign.
-
Tianyan Pharmaceutical's anti-CTLA-4 antibody was approved for clinical use in the U.S.
Time of Update: 2022-01-03
On November 30, Tianyan Pharmaceuticals announced that the US FDA has approved its Phase 1b/2 clinical trial application for the combination therapy of its anti-CTLA-4 monoclonal antibody (mAb) ADG116 and anti-PD-1 antibody pembrolizumab .
-
Holding a group to resist the cold winter, a wave of "cooperation" between domestic pharmaceutical companies has begun
Time of Update: 2022-01-03
For example, on November 22, Connoa announced that it has exclusively authorized the innovative drug CM326 (a recombinant humanized monoclonal antibody against TSLP) with CSPC in moderate to severe asthma and chronic obstructive pulmonary disease (COPD) and other respiratory diseases A formal agreement was signed for development and commercialization .
-
The homogeneity of domestic innovative drugs is serious, and the "quality" needs to be accelerated
Time of Update: 2022-01-03
In addition to making competitive, differentiated, and valuable products, the industry believes that domestic innovative companies should also set their sights on overseas markets .
-
The first KRAS inhibitor license out!
Time of Update: 2022-01-03
According to the terms of the agreement, Jiyu Medicine will exclusively license the development, production and commercialization rights of the KRAS inhibitor JMKX1899 with independent intellectual property rights outside the Greater China Region to Huya, and the relevant rights and interests of JMKX1899 in the Greater China Region will remain with Jimin Trust.
-
A large number of pharmaceutical companies announced layoffs. What are the reasons?
Time of Update: 2022-01-03
In addition to November, many pharmaceutical companies announced layoffs in October .
According to Fierce pharma on October 13, 2021, Ardelyx plans to lay off 65% of its employees because the FDA will not provide clear information to biopharmaceutical companies on the prospects of its chronic kidney disease drugs .
-
What are the symptoms of being infected with Omi Keron strain?
Time of Update: 2022-01-03
The WHO said on the 28th that it is still unclear whether the Omi Kiron strain will cause more serious diseases, and it is cooperating with experts to understand the impact of the Omi Kiron strain on current epidemic prevention measures, including vaccination .
-
Two specifications of Jianmin Biantong Capsules are cancelled
Time of Update: 2022-01-02
Recently, the Shanxi Provincial Pharmaceutical Equipment Centralized Bidding and Procurement Center issued a notice on publicizing Jianmin Pharmaceutical Group Co.
bid for two drug product regulations to apply for cancellation of the platform's online procurement qualification.
-
API companies have expanded production, or accelerated the innovation and upgrade of the pharmaceutical machinery industry
Time of Update: 2022-01-02
API companies have expanded production, forcing the pharmaceutical machinery industry to accelerate innovation and upgrading (Source: Pharmaceutical Network) Many API projects over 100 million yuan have started construction.
-
The concept of vaccines can never escape the "day trip"
Time of Update: 2022-01-02
Author: CephalosporinThere have been several daylight scenes since the first exposure of "Omi Keron" in the world. As the most mutated new coronavirus virus so far, it is twice as much as the Delta m
-
Over 700 million yuan in antibiotic varieties, ushering in another over-rated pharmaceutical company!
Time of Update: 2022-01-02
On December 1, Huluwa Pharmaceuticals issued an announcement stating that the company had recently received the "Drug Supplementary Application Approval Notice" on "Azithromycin for Injection" approved and issued by the State Food and Drug Administration.
-
Nuggets overweight/obesity drug market GLP-1 receptor agonists do their part
Time of Update: 2022-01-02
At present, a variety of GLP-1 receptor agonists in China have been developed for overweight/obesity.
The drug is a long-acting molecule that is injected once a week and has been shown to effectively control blood sugar and reduce the weight of subjects in early clinical trials .
